

Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Centers for Disease Control and Prevention	Grant / Contract	Self
<i>Recipient Name:</i> Riley Hospital for Children/Indiana University School of Medicine/Trustees of Indiana University <i>Grant / Contract Purpose:</i> Other - public health surveillance		<i>Recipient Type:</i> Institution <i>Grant / Contract Description:</i> <i>Additional Information:</i> I received funding from the CDC to Riley Hospital for Children in support of this work and that the funding was specifically for the work described in the paper

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

Yes.

 - Please describe those relationships.**

I received funding from the CDC to Riley Hospital for Children in support of this work and that the funding was specifically for the work described in the paper
- What is the manuscript title?**

Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Centers for Disease Control and Prevention	Grant / Contract	Self

Recipient Name: Nationwide Children's Hospital
Grant / Contract Description: We receive funding from the CDC to our institution.
Additional Information:

Recipient Type: Institution
Grant / Contract Purpose: Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Centers for Disease Control and Prevention	Grant / Contract	Self
<i>Recipient Name:</i> Baylor College of Medicine <i>Grant / Contract Description:</i> Patient enrollment <i>Additional Information:</i>	<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Other - public health surveillance	

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-17995

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Centers for Disease Control and Prevention	Grant / Contract	Self
<i>Recipient Name:</i> Rady Children's Hospital/UC San Diego <i>Grant / Contract Description:</i> Funding specifically for work described in the paper <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Other - public health surveillance

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-17995

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Centers for Disease Control and Prevention	Grant / Contract	Self
<i>Recipient Name:</i> University of Miami Miller School of Medicine <i>Grant / Contract Description:</i> Miami site contract for the purpose of public health surveillance <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Other - public health surveillance

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Centers for Disease Control and Prevention	Grant / Contract	Self
<i>Recipient Name:</i> Children's Hospital of Philadelphia <i>Grant / Contract Description:</i> COVID-19 Vaccine Effectiveness <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Other - Public health surveillance

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Centers for Disease Control and Prevention	Grant / Contract	Self
<i>Recipient Name:</i> University of Nebraska <i>Grant / Contract Description:</i> Payment for the work that lead to the paper <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
NIH Clinical Center	Grant / Contract	Self
<i>Recipient Name:</i> University of Nebraska <i>Grant / Contract Description:</i> Subcontract of NIH funding to study influenza <i>Additional Information:</i> Given clinical similarities some of the work done for this sub-contract on the grant helped lead to the data in this paper		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Centers for Disease Control and Prevention	Grant / Contract	Self
<i>Recipient Name:</i> University of California San Francisco <i>Grant / Contract Description:</i> A public health study of COVID-19 vaccine effectiveness in preventing severe pediatric COVID-19		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i>

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
AerogenPharma	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Unfunded		<i>Description:</i> Scientific consultant for product development

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
Yes.
 - Please describe those relationships.**
My institution received financial compensation for this work from the Center for Disease Control and Prevention.
- What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Abbott Laboratories	Stock	Other - Combined self/spouse account
<i>Additional Information:</i>		
Centers for Disease Control and Prevention	Grant / Contract	Other - CDC funding to university to cover costs of research
<i>Recipient Name:</i> University of Arizona College of Medicine- Tucson		<i>Recipient Type:</i> Institution
<i>Grant / Contract Description:</i> Funding for Pediatric Covid-19 related research		<i>Grant / Contract Purpose:</i> Research
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Centers for Disease Control and Prevention	Grant / Contract	Self
<i>Recipient Name:</i> Saint Barnabas Medical Center <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Other - public health surveillance

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Centers for Disease Control and Prevention	Grant / Contract	Self
<i>Recipient Name:</i> Vanderbilt University Medical Center <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
SANOPI PASTEUR INC.	Grant / Contract	Self
<i>Recipient Name:</i> Vanderbilt University Medical Center <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
Yes.
 - Please describe those relationships.**
Sanofi Pasteur- received grant funding for an influenza vaccine trial
- What is the manuscript title?**
Manuscript title: Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents Manuscript #: 21-17995
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Centers for Disease Control and Prevention	Grant / Contract	Self
<i>Recipient Name:</i> Central Michigan University <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Other - Public Health Surveillance

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine Against Critical COVID-19 in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-17995

Summary of Interests

Entity	Type	Interest Held By
BioFire Diagnostics, LLC	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Consultant-lecturer
Centers for Disease Control and Prevention	Grant / Contract	Self
<i>Recipient Name:</i> University of Mississippi Medical Center <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Other - public health surveillance
Dynamed	Other	Self
<i>Category:</i> Other <i>Additional Information:</i> have been working with DYNAMED since 2018, the above refers to renewed contract. DYNAMED is similar to Up to Date, but writers/editors/medical consultants are NOT awarded by content access/viewed.		<i>Description:</i> "triage" of articles that are added for content to Dynamed.com

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Centers for Disease Control and Prevention	Grant / Contract	Other - Institution
<i>Recipient Name:</i> University of Minnesota <i>Grant / Contract Description:</i> Support for Overcoming COVID-19 Vaccine Effectiveness study <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Centers for Disease Control and Prevention	Grant / Contract	Self
<i>Recipient Name:</i> Arkansas Children's Research Institute <i>Grant / Contract Description:</i> Overcoming COVID <i>Additional Information:</i> Institutional Support		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Other - Public health surveillance

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Centers for Disease Control and Prevention	Grant / Contract	Self
<i>Recipient Name:</i> Emory University <i>Grant / Contract Description:</i> Funds specifically for the work described in the current manuscript. <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Other - public health surveillance
Janssen Pharmaceuticals, Inc	Grant / Contract	Self
<i>Recipient Name:</i> Emory University <i>Grant / Contract Description:</i> Funds from NIH for his work as a co-investigator on clinical trials of Janssen COVID-19 vaccine		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i>
Moderna	Grant / Contract	Self
<i>Recipient Name:</i> Emory University <i>Grant / Contract Description:</i> Funds from NIH for his work as a co-investigator on clinical trials of Moderna COVID-19 vaccine		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i>
Pfizer	Grant / Contract	Self
<i>Recipient Name:</i> Emory University <i>Grant / Contract Description:</i> Funds from Pfizer for his work as a co-investigator on clinical trials of Pfizer COVID-19 vaccine.		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i>

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Centers for Disease Control and Prevention	Grant / Contract	Other - Institution
<i>Recipient Name:</i> UAB <i>Grant / Contract Description:</i> Funding for conduct of research <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Centers for Disease Control and Prevention	Grant / Contract	Self
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> 75D30120C07725-01 <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Other - public health surveillance
Division of Intramural Research, National Institute of Allergy and Infectious Diseases	Grant / Contract	Self
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> AI144301-01 <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Centers for Disease Control and Prevention	Grant / Contract	Other - Principal Investigator received funds
<i>Recipient Name:</i> Cindy Darnell Bowens		<i>Recipient Type:</i>
<i>Grant / Contract Description:</i>		<i>Grant / Contract Purpose:</i>
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Centers for Disease Control and Prevention	Grant / Contract	Self
<i>Recipient Name:</i> MUSC <i>Grant / Contract Description:</i> <i>Additional Information:</i> received funding from the CDC to your institution in support of this work and that was the funding specifically for the work described in the paper		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.
- What is the manuscript title?**

Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Centers for Disease Control and Prevention	Grant / Contract	Self
<i>Recipient Name:</i> University of Colorado School of Medicine <i>Grant / Contract Description:</i> <i>Additional Information:</i> Funding from the CDC was specifically for the work described in this manuscript.		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-17995

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Centers for Disease Control and Prevention	Grant / Contract	Self

Recipient Name: Boston Children's Hospital
Grant / Contract Description: Contract from CDC to Boston Children's Hospital coordinating center
Additional Information:

Recipient Type: Institution
Grant / Contract Purpose: Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Centers for Disease Control and Prevention	Grant / Contract	Self
<i>Recipient Name:</i> Akron Children's Hospital Research Institute <i>Grant / Contract Description:</i> Grant funding for COVID and Influenza Research <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
National Institutes of Health	Grant / Contract	Self
<i>Recipient Name:</i> Akron Children's Hospital Research Institute <i>Grant / Contract Description:</i> Research grant for critical illness with influenza <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
 Yes.
 - Please describe those relationships.
 My institution received funding from the CDC in support specifically for the work described in the paper submitted.
- What is the manuscript title?
 Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?
 No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-17995

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AstraZeneca	Grant / Contract	Self
<i>Recipient Name:</i> Children's Hospital Los Angeles <i>Grant / Contract Description:</i> RSV studies <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Centers for Disease Control and Prevention	Grant / Contract	Self
<i>Recipient Name:</i> Children's Hospital Los Angeles <i>Grant / Contract Description:</i> COVID-19 Vaccine Effectiveness Study - Support for work described in the manuscript <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i>
National Institutes of Health	Grant / Contract	Self
<i>Recipient Name:</i> Children's Hospital Los Angeles <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Pfizer	Grant / Contract	Self
<i>Recipient Name:</i> Children's Hospital Los Angeles <i>Grant / Contract Description:</i> Pneumococcus studies <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
SANOFI PASTEUR INC.	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>
Seqirus USA Inc	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>

Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
2. **What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine Against Critical COVID-19 in Adolescents
3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-17995

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents

3. **Are you the corresponding author?**

Yes.

a. **Please list the other authors' names here.**

Samantha M. Olson, MPH; Margaret M. Newhams, MPH; Natasha B. Halasa, MD; Ashley M. Price, MPH; Julie A. Boom, MD; Leila C. Sahni, PhD, MPH; Pia S. Pannaraj, MD, MPH; Katherine Irby, MD; Tracie C. Walker, MD; Stephanie P. Schwartz, MD; Aline B. Maddux, MD; Elizabeth H. Mack, MD; Tamara T. Bradford, MD; Jennifer E. Schuster, MD; Ryan A. Nofziger, MD; Melissa A. Cameron, MD; Kathleen Chiotos, MD, MSCE; Melissa L. Cullimore, MD; Shira J. Gertz, MD; Emily R. Levy, MD; Michele Kong, MD; Natalie Z. Cvijanovich, MD; Mary A. Staat, MD; Satoshi Kamidani, MD; Brandon M. Chatani, MD; Samina S. Bhumbra, MD; Katherine E. Bline, MD; Mary G. Gaspers, MD, MPH; Charlotte V. Hobbs, MD; Sabrina M. Heidemann, MD; Mia Maamari, MD; Heidi R. Flori, MD; Janet R. Hume, MD; Matt S. Zinter, MD; Kelly N. Michelson, MD; Laura D. Zambrano, PhD; Angela P. Campbell, MD, MPH; Adrienne G. Randolph, MD;

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-17995

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Centers for Disease Control and Prevention	Grant / Contract	Self
<i>Recipient Name:</i> Boston Children's Hospital <i>Grant / Contract Description:</i> Contract for investigating COVID-19-related complications in children <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Other - Public Health Surveillance

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Centers for Disease Control and Prevention	Grant / Contract	Self
<i>Recipient Name:</i> Baylor College of Medicine <i>Grant / Contract Description:</i> Contract for subject enrollment in Overcoming COVID-19 <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Other - Public health surveillance

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-17995

Summary of Interests

Entity	Type	Interest Held By
Centers for Disease Control and Prevention	Grant / Contract	Self
<i>Recipient Name:</i> Children's Mercy Kansas City <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Merck	Grant / Contract	Self
<i>Recipient Name:</i> Children's Mercy Kansas City <i>Grant / Contract Description:</i> RSV monoclonal antibody clinical trial <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Centers for Disease Control and Prevention	Grant / Contract	Self
<i>Recipient Name:</i> University of North Carolina at Chapel Hill <i>Grant / Contract Description:</i> <i>Additional Information:</i> I received funding from the CDC to UNC in support of this work and that was the funding specifically for the work described in this paper.		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Other - Public Health Surveillance

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Centers for Disease Control and Prevention	Other	Self
<i>Category:</i> Other		<i>Description:</i> funding was given to my institution, Cincinnati Children's to do the work outlined in the manuscript
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Centers for Disease Control and Prevention	Grant / Contract	Self
<i>Recipient Name:</i> University of North Carolina <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Other - public health surveillance

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-17995

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-17995

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Centers for Disease Control and Prevention	Grant / Contract	Self
<i>Recipient Name:</i> University of California, San Francisco <i>Grant / Contract Description:</i> CDC surveillance of COVID-19 <i>Additional Information:</i> grant for research/public health surveillance activities		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Other - public health surveillance

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Effectiveness of BNT162b2 Vaccine against Critical COVID-19 in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

